Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143692 | 1.00 | AHCY (0.37) | AHCYP2RY12ADORA1 | |
| SCHEMBL29687929 | 1.00 | AHCY (0.37) | AHCYP2RY12ADORA1 | |
| SCHEMBL1838603 | 0.81 | P2RY12 (0.49) | AHCYP2RY12 | |
| SCHEMBL29688154 | 0.81 | P2RY12 (0.49) | AHCYP2RY12 | |
| SCHEMBL29688156 | 0.79 | P2RY12 (0.48) | AHCYP2RY12 | |
| SCHEMBL16107326 | 0.79 | P2RY12 (0.48) | AHCYP2RY12 | |
| SCHEMBL1828941 | 0.79 | P2RY12 (0.48) | AHCYP2RY12 | |
| SCHEMBL3614559 | 0.79 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL29688107 | 0.79 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL17213354 | 0.73 | AHCY (0.34) | AHCYP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | ASTRAZENECA UK LIMITED (GB) | 2014-10-02 | — | — | US | claimed |
| EP-2322513-A2 | Intermediates | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| EP-1135391-B1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | GP6, THPO, P2RY6 | AHCY 3300/4885P2RY12 11/4885ADORA1 214/4885 |
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | AHCY 2881/4885P2RY12 72/4885ADORA1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.